Format

Send to:

Choose Destination
See comment in PubMed Commons below
IDrugs. 2006 Feb;9(2):128-35.

Neramexane (merz pharmaceuticals/forest laboratories).

Author information

  • 1Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. rammes@mpipsykl.mpg.de

Abstract

Merz Pharmaceuticals GmbH and Forest Laboratories Inc are developing neramexane, an oral N-methyl-D-aspartate antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

PMID:
16523403
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk